Impact Biomedical IBO
NYSE IBO
$5.46 -0.14 (-2.50%)
As of: Oct 1, 2026 · 3:57 PM EDT

Impact Biomedical (IBO) EBITDA Margin (2022 - 2026)

Updated

Impact Biomedical (IBO) reported EBITDA Margin of -13933.33% for Q2 2026, down 1576.19 percentage points from -12357.14% a year earlier but up 14695.24 percentage points from the prior quarter.

Analysis

Impact Biomedical (IBO) EBITDA Margin (2022 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Impact Biomedical's EBITDA Margin came in at -11277.14%, up 38529.87 percentage points year-over-year; for FY2022, it came in at -4582.00%.

  • Five-year quarterly EBITDA Margin spans a low of -28628.57% in Q1 2026 and a high of -944.00% in Q2 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 35.95%
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 49.01%
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 6.02%
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 33.11%
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 46.01%
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -124.26%
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 39.16%
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 39.10%
10 Impact Biomedical 598.41 Mn 601.61 Mn 2,000.00 -13,933.33%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -13,933.33%
Mar 31, 2026 -28,628.57%
Sep 30, 2025 -3,666.67%
Jun 30, 2025 -12,357.14%
Jun 30, 2022 -944.00%
API Access

Impact Biomedical EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=IBO&period=max&api_key=YOUR_API_KEY